ABVC BIOPHARMA, INC.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $681K+174.4% | $248K+312.9% | $60K-29.4% | $85K-98.5% | $5.8M |
| Restricted cash | $646K+4.9% | $615K-6.3% | $657K-49.7% | $1.3M | — |
| Short-term investments | $64K-0.6% | $65K-18.4% | $79K+4.6% | $76K-29.9% | $108K |
| Prepaid expense and other current assets | $347K+260.3% | $96K-4.8% | $101K-32.7% | $150K-71.6% | $528K |
| Total Current Assets | $2.5M+14.8% | $2.2M+31.6% | $1.7M-44.5% | $3.0M-61.0% | $7.7M |
| Property and equipment, net | $12.8M+2411.4% | $511K-10.2% | $569K-0.8% | $574K+9.1% | $526K |
| Operating lease right-of-use assets | $1.9M+198.8% | $640K-20.9% | $809K-30.3% | $1.2M-21.1% | $1.5M |
| Long-term investments | $1.9M-16.8% | $2.3M-10.6% | $2.5M+200.2% | $842K-9.7% | $933K |
| Prepayment for long-term investments | $1.1M+0.0% | $1.1M-11.8% | $1.3M-55.1% | $2.8M+146.2% | $1.2M |
| Prepayment for asset acquisition | $692K+0.0% | $692K+0.0% | $692K | — | — |
| Other non-current assets | $117K-12.1% | $133K-5.7% | $141K | — | — |
| Total Assets | $21.1M+179.3% | $7.5M-3.1% | $7.8M-18.7% | $9.6M-30.1% | $13.7M |
| Short-term bank and other loans | $756K-10.1% | $840K-6.6% | $899K-52.5% | $1.9M | — |
| Accrued expenses and other current liabilities | $4.2M+18.6% | $3.5M-1.1% | $3.5M+22.0% | $2.9M+123.7% | $1.3M |
| Contract liabilities | $13K-84.5% | $81K+2.0% | $80K+623.7% | $11K | — |
| Operating lease liabilities – current | $318K-21.3% | $404K+0.4% | $402K+8.8% | $369K+6.4% | $347K |
| Tax payable | $12K | — | — | — | — |
| Convertible notes payable – third parties, net | $559K-41.2% | $950K+7.2% | $887K | — | — |
| Total Current Liabilities | $6.2M-6.0% | $6.6M+7.5% | $6.1M+10.1% | $5.5M+50.1% | $3.7M |
| Tenant security deposit | $22K | — | $22K+171.7% | $8K-24.6% | $11K |
| Operating lease liability – non-current | $1.6M+576.0% | $237K-41.9% | $407K-48.5% | $792K-29.6% | $1.1M |
| Total Liabilities | $7.8M+13.9% | $6.8M+4.4% | $6.5M+3.0% | $6.3M+31.4% | $4.8M |
| Common stock, $0.001 par value, 100,000,000 authorized, 25,053,193 and 13,868,484 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $25K+80.7% | $14K+74.7% | $8K+141.6% | $3K-88.6% | $29K |
| Stock to be issued | $359K+1056.6% | $31K | — | — | — |
| Additional paid-in capital | $96.0M+22.2% | $78.6M+6.2% | $74.0M+8.9% | $67.9M+16.9% | $58.1M |
| Accumulated deficit | -$76.9M-11.5% | -$68.9M-7.7% | -$64.0M-16.7% | -$54.9M-42.7% | -$38.5M |
| Accumulated other comprehensive income | $488K+9.4% | $446K-13.7% | $516K-0.1% | $517K-4.2% | $540K |
| Treasury stock | -$8.9M+0.0% | -$8.9M-0.1% | -$8.9M+2.2% | -$9.1M+0.0% | -$9.1M |
| Total Stockholders’ equity | $11.1M+806.2% | $1.2M-21.1% | $1.6M-49.8% | $3.1M-65.0% | $8.8M |
| Noncontrolling interest | $2.2M+535.2% | -$502K-67.0% | -$301K-318.6% | $138K+415.4% | $27K |
| Total Equity | $13.3M+1736.8% | $724K-42.2% | $1.3M-61.3% | $3.2M-63.5% | $8.9M |
| Total Liabilities and Equity | $21.1M+179.3% | $7.5M-3.1% | $7.8M-18.7% | $9.6M-30.1% | $13.7M |
| Related Party | |||||
| Due from related parties – current | $763K-33.9% | $1.2M+54.5% | $748K+45.5% | $514K | — |
| Due to related parties | $106K-86.3% | $773K+346.5% | $173K-51.9% | $360K-8.5% | $393K |
| Convertible notes payable – related parties, net | $240K | — | $887K | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.